Colorectal cancer (CRC) is the third most common cancer globally, with 20%-25%of patients diagnosed at stage IV, significantly affecting overall survival (OS).Only 14% of stage IV patients survive for 5 years with pal...Colorectal cancer (CRC) is the third most common cancer globally, with 20%-25%of patients diagnosed at stage IV, significantly affecting overall survival (OS).Only 14% of stage IV patients survive for 5 years with palliative chemotherapy.However, the role of liver transplantation (LT) in the management of CRC livermetastasis (CRCLM) is an evolving area of interest. Recent advancements inoncologic outcomes and clinical understanding have prompted the re-evaluationof LT as a viable treatment option for CRCLM. A promising result from someprospective pilot studies reported a 5-year OS rate of 60% after LT for patientswith CRCLM. Key factors influencing eligibility include tumor biology, absence ofextrahepatic disease, and the patient's performance status. By synthesizing thelatest research findings, we aim to provide a comprehensive overview that summarizesthe most relevant data related to the clinical outcomes of patients whounderwent LT for CRCLM. We aim to provide a comprehensive overview by synthesizingthe latest research findings. This review discusses the inclusion criteriaand eligibility for LT in CRCLM, which are of great importance to patient outcomes.展开更多
基金Supported by the European Union-NextGenerationEU,through the National Recovery and Resilience Plan of the Republic of Bulgaria,No.BG-RRP-2.004-0008.
文摘Colorectal cancer (CRC) is the third most common cancer globally, with 20%-25%of patients diagnosed at stage IV, significantly affecting overall survival (OS).Only 14% of stage IV patients survive for 5 years with palliative chemotherapy.However, the role of liver transplantation (LT) in the management of CRC livermetastasis (CRCLM) is an evolving area of interest. Recent advancements inoncologic outcomes and clinical understanding have prompted the re-evaluationof LT as a viable treatment option for CRCLM. A promising result from someprospective pilot studies reported a 5-year OS rate of 60% after LT for patientswith CRCLM. Key factors influencing eligibility include tumor biology, absence ofextrahepatic disease, and the patient's performance status. By synthesizing thelatest research findings, we aim to provide a comprehensive overview that summarizesthe most relevant data related to the clinical outcomes of patients whounderwent LT for CRCLM. We aim to provide a comprehensive overview by synthesizingthe latest research findings. This review discusses the inclusion criteriaand eligibility for LT in CRCLM, which are of great importance to patient outcomes.
